Heidi Fields - 10 Jun 2022 Form 4 Insider Report for Icosavax, Inc.

Reporting relationship: Director
Issuer ticker: N/A
Reported as of: 10 Jun 2022
Net transaction value: $0
SEC form: 4
Accepted by SEC: 14 Jun 2022, 17:01:47 UTC
Prior SEC filing: 27 May 2022
Next SEC filing: 28 Nov 2022
Source filing: View source filing
Reporting owner signature: /s/ Elizabeth Bekiroglu, Attorney-in-Fact for Heidi Fields

Key filing fact

Heidi Fields filed Form 4 for Icosavax, Inc. on 14 Jun 2022.

Key facts

This page summarizes Heidi Fields's Form 4 filing for Icosavax, Inc..
2 reported transactions and 1 derivative row are listed below.
Accepted by SEC: 14 Jun 2022, 17:01.

Change

Previous filing in this sequence was filed on 27 May 2022.
Current net transaction value: $0.

Research use

This tells you what this filing adds before you inspect full transaction and derivative tables.
You can trace every row back to the original SEC filing document.

Evidence

Filed on Form 4

Ownership activity is grounded in SEC Form 4 disclosures.

View source filing

Reported non-derivative transactions

Shares, units, or other non-derivative securities reported in this filing.

ICVX transaction

Common Stock

Award

Transaction value: $0
Shares: +5,543
Change %: +63%
Price: $0.000000
Shares after: 14,293
Date: 10 Jun 2022
Ownership: Direct
Footnotes: F1

Reported derivative securities

Options, warrants, convertible securities, or similar derivative positions disclosed in the filing.

ICVX transaction Derivative

Stock Option (Right to Buy))

Award

Transaction value: $0
Shares: +22,278
Change %
Price: $0.000000
Shares after: 22,278
Date: 10 Jun 2022
Ownership: Direct
Underlying class: Common Stock
Underlying amount: 22,278
Exercise price: $6.25
Footnotes: F2

^* marks a reported price that did not pass the local price check.

Additional SEC filing notes

Filing notes and footnotes

Explanation of responses 2 footnotes

Footnote F1

Represents restricted stock units ("RSUs") which will vest on the first to occur of (A) the first anniversary of the date of grant or (B) the next occurring annual meeting of the Issuer's stockholders, subject to the Reporting Person's continuous service on the board of directors of the Issuer through such vesting date. Each RSU represents a contingent right to receive one share of common stock of the Issuer and the RSUs have no expiration date.

Footnote F2

1/12th of the total number of shares of common stock subject to the option vest monthly following June 10, 2022, the vesting commencement date, provided if the next occurring annual meeting of the Issuer's stockholders occurs prior to the full vesting of the option, any remaining options will vest on the date of such annual meeting, subject to the Reporting Person's continuous service on the board of directors of the Issuer through such vesting date.